LEXINGTON, Mass., Sept. 2, 2015 /PRNewswire/ -- Pulmatrix, Inc. (NASDAQ: PULM) has been granted U.S. patent 9,119,778, for the Company’s underlying iSPERSE inhaled dry powder technology. The patent broadly covers small, dense and dispersible dry powders that are comprised of proprietary combinations of divalent cation salts and excipients. These patented dry powders have the potential to enable and/or improve new approaches for the treatment of lung disease and to facilitate greater efficiency in the delivery of pharmaceuticals to the lungs. The Company now has 37 issued patents worldwide covering the iSPERSE technology through at least 2030.
“Our issued patents and pending applications provide multiple layers of protection for our formulation concepts for small dense dry powders that encompass a wide array of pharmaceutical agents and can be efficiently delivered to the lungs,” said Robert W. Clarke, Ph.D., chief executive officer of Pulmatrix. “This most recent issuance strengthens and expands our IP protection to cover applications where divalent salts are required to optimize the therapeutic effect of iSPERSE with certain active pharmaceutical ingredients.”
“The iSPERSE technology combines different salt excipients with particle engineering to create dry particles with unique properties for lung delivery. This new granted patent builds and expands on previous patent grants worldwide and provides significant protection for one of the two major foundations of the technology, that being the use of divalent cations as principal excipients,” said David L. Hava, Ph.D., chief scientific officer of Pulmatrix.
Pulmatrix’s iSPERSE (inhaled Small Particles Easily Respirable and Emitted) technology has the potential to solve significant limitations of other inhalation technologies available today, such as nebulizers, metered dose inhalers, and conventional lactose blend dry powder inhalers. iSPERSE particles are engineered to be small, dense, and easily dispersible upon inhalation, thereby delivering the drugs more efficiently to the airways. This targeted airway delivery of drugs also reduces systemic exposure and potential side effects. Importantly, unlike other traditional inhalation technologies, iSPERSE is also flow rate independent, providing reliable dose delivery across patient populations regardless of the status of patient lung function.
About Pulmatrix
Pulmatrix is a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary disease using its patented iSPERSE technology. The Company’s proprietary product pipeline is focused on advancing treatments for rare diseases, including PUR1900, an inhaled anti-fungal for patients with cystic fibrosis (CF), as well as PUR1500, an inhaled product for the treatment of idiopathic pulmonary fibrosis. In addition, Pulmatrix is pursuing opportunities in major pulmonary diseases through collaboration with partners. This includes PUR0200, a branded generic in clinical development for chronic obstructive pulmonary disease (COPD) in collaboration with Mylan N.V., and other potential first-in-class treatments. Pulmatrix’s product candidates are based on iSPERSE, its proprietary dry powder delivery platform, which seeks to improve therapeutic delivery to the lungs by maximizing local concentrations and reducing systemic side effects to improve patient outcomes.
FORWARD-LOOKING STATEMENTS
Certain statements in this letter that are forward-looking and not statements of historical fact are forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of forward-looking terms such as “anticipates,” “assumes,” “believes,” “can,” “could,” “estimates,” “expects,” “forecasts,” “guides,” “intends,” “is confident that,” “looks forward,” “may,” “plans,” “seeks,” “projects,” “targets,” and “would” or the negative of such terms or other variations on such terms or comparable terminology. Pulmatrix cautions that such statements involve risks and uncertainties that may materially affect Pulmatrix’s results of operations. Such forward-looking statements are based on the beliefs of management as well as assumptions made by and information currently available to management. Actual results could differ materially from those contemplated by the forward-looking statements as a result of certain factors, including but not limited to the ability to enforce issued patents and prosecute new patents in order to maintain a proprietary position or freedom to operate, the ability to establish that potential products are efficacious or safe in preclinical or clinical trials; the ability to obtain appropriate or necessary governmental approvals to market potential products; the ability to obtain future funding for developmental products and working capital; and the ability to secure and enforce legal rights related to the Pulmatrix’s products. A discussion of these and other factors, including risks and uncertainties with respect to Pulmatrix, is set forth in the registration statement on Form S-4 filed by Pulmatrix on April 15, 2015, as amended. Pulmatrix disclaims any intention or obligation to revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/pulmatrix-issued-new-composition-of-matter-patent-covering-isperse-technology-300136524.html
SOURCE Pulmatrix, Inc.
Help employers find you! Check out all the jobs and post your resume.
